Related by context. All words. (Click for frequent words.) 66 teriflunomide 65 florbetaben 65 Azedra 64 Trofex 64 varespladib 63 clevidipine 63 echocardiographic 63 tanespimycin 63 pharmacodynamic effects 62 phase IIa clinical 62 fosbretabulin 62 AdreView 62 HuMax EGFr 62 ZOLINZA 61 plasma kallikrein inhibitor 61 NATRECOR R 61 Targretin capsules 61 icatibant 61 Trandolapril 61 MGd 61 HIF PH inhibitors 61 florbetapir 61 eniluracil 61 ruxolitinib 61 phase IIb clinical 61 cannabinor 61 NATRECOR ® 61 elotuzumab 61 CaPre TM 61 cediranib 61 preclinically 60 antithrombotic therapies 60 pharmacologic stress 60 rFVIIa 60 thorough QT 60 favorable pharmacokinetic profile 60 platelet inhibition 60 Florbetapir 60 galiximab 60 flurpiridaz F 60 pharmacokinetic PK profile 60 VAPRISOL 60 alvespimycin 60 atacicept 60 EOquin TM 60 Capesaris 60 Diovan HCT 60 Olmesartan 60 TOLAMBA 60 PERSEUS 60 EP #R 60 AZILECT ® 60 riociguat 60 SPC# [001] 60 YONDELIS 60 Vidaza azacitidine 60 brivaracetam 60 ProSavin 60 ganetespib 60 zotarolimus 60 CA9 SCAN 60 rNAPc2 59 ponatinib 59 tolvaptan 59 intravascular ultrasonography 59 efficacy tolerability 59 dacetuzumab 59 bicifadine 59 TH# [003] 59 CorVue ™ 59 Silodosin 59 Elocalcitol 59 Androxal TM 59 CBLC# 59 anti angiogenic agents 59 neratinib 59 Nanobody 59 intracoronary 59 INCB# [003] 59 GFT# 59 pharmacodynamic 59 ALA PDT 59 lomitapide 59 ACAPODENE 59 Dasatinib 59 antiarrhythmic drug 59 AeroLEF TM 59 Dacogen decitabine 59 Degarelix 59 NP2 Enkephalin 59 PSMA ADC 59 AERx iDMS 59 transthoracic 59 cortical stimulation 59 AGHD 59 iloprost 59 Phase IIb III 59 pharmacodynamic PD 59 IRX 2 59 PRT# 59 ATACAND 59 pomalidomide 59 mertansine 59 anti arrhythmic 59 ticagrelor Brilinta 59 STRIDE PD 59 Amrubicin 59 ADAGIO study 59 inhaled iloprost 59 Phase Ib study 59 gefitinib Iressa 58 prospective multicenter 58 BMS# 58 JAK inhibitor 58 oral rivaroxaban 58 phase IIb study 58 vidofludimus 58 olmesartan 58 biomolecular interactions 58 BRAF inhibitor 58 myocardial perfusion imaging 58 preclinical pharmacokinetic 58 canagliflozin 58 Phase Ib clinical 58 metaglidasen 58 molecular biomarkers 58 REG1 58 bardoxolone methyl 58 pharmacokinetics PK 58 antiangiogenic therapy 58 Chemophase 58 BRIM2 58 PRX# 58 placebo controlled clinical 58 renoprotective 58 PRIMO CABG 58 ELACYT 58 radiation dosimetry 58 DACH platinum 58 SNT MC# 58 oral prodrug 58 antihypertensive therapies 58 ToGA 58 pharmacokinetic PK study 58 liposomal doxorubicin 58 EVIZON 58 PS# [001] 58 levosimendan 58 pertuzumab 58 CIMZIA ™ 58 REMINYL ® 58 preclinical efficacy 58 antiangiogenic agents 58 Aliskiren 58 CCX# 58 Triolex 58 ATL# [001] 58 Aflibercept 58 RE LY ® 58 antithrombotic agents 58 antiarrhythmic 58 scintigraphic 58 bortezomib Velcade 58 alpha blocker 58 Safinamide 58 obatoclax 58 clinical pharmacology studies 58 Toraymyxin TM 58 GAMMAGARD 58 Vernakalant 58 Insulin PH# 58 liposomal formulation 58 genomic biomarker 58 octreotide acetate 58 TBC# 58 Spiegelmer ® 58 prasugrel Effient 58 ThGRF 58 Pemetrexed 58 OraTest 58 indibulin 58 Lp PLA 2 57 AEGR 57 CRMD# 57 mecamylamine 57 pharmacokinetic PK 57 vorinostat 57 SPECT imaging 57 SCH # 57 paricalcitol 57 busulfan 57 interferon beta therapy 57 antihypertensive agents 57 QTc prolongation 57 RSD# oral 57 CytoFabTM 57 PSN# [001] 57 DUROS 57 bevasiranib 57 PRECISE 57 GLP1 agonist 57 mTOR inhibition 57 ZD# [001] 57 enzastaurin 57 BrachySil TM 57 XmAb# 57 Fulvestrant 57 cinacalcet 57 alteplase 57 Solorel TM 57 myocardial necrosis 57 ADVANCE PD 57 Aplidin 57 Fondaparinux 57 cetuximab Erbitux 57 Mipomersen 57 plasma renin activity 57 biomarker assay 57 pain palliation 57 Anacetrapib 57 rosuvastatin Crestor 57 BNC# 57 Solorel 57 Firazyr 57 #F AV 57 iniparib 57 Sibutramine Cardiovascular Outcomes 57 pharmacodynamic markers 57 perfusion MRI 57 PEG SN# 57 cardiac repolarization 57 adipiplon 57 eprotirome 57 CUSTOM III 57 KRN# 57 viral kinetics 57 PET tracer 57 TREDAPTIVE 57 Darapladib 57 PSN# [002] 57 HuMax CD# 57 Altropane 57 phase IIIb 57 AZOR 57 QuadraSphere 57 CR# vcMMAE 57 MAGE A3 ASCI 57 Phase #b/#a 57 F FDG PET 57 Orazol 57 Sapacitabine 57 deforolimus 57 Acute Ischemic Stroke 57 radiolabeled 57 romidepsin 57 CA4P 57 Pimavanserin 57 postapproval 57 DAVANAT 57 tecarfarin 57 ASTEROID 57 SILENOR 57 CARE HF 57 ENMD # 57 bile acid sequestrant 57 RG# [001] 57 Zybrestat 57 torcetrapib atorvastatin 57 Zenvia Phase III 57 ARIKACE ™ 57 transcranial Doppler ultrasound 57 xanthine oxidase inhibitor 57 Panzem 57 LY# [002] 57 treprostinil 57 Phase IIa trial 57 Magnetic resonance 57 Targretin 57 multicenter clinical 57 Val HeFT 57 vivo potency 57 ATL/TV# 57 Corus CAD 57 Pharmacodynamic 57 Triapine R 57 OvaRex ® MAb 57 Enzastaurin 57 electrocardiography ECG 57 multicenter Phase II 57 MEVACOR 57 VADT 57 endothelin receptor antagonists 57 midstage clinical 57 Annexin V 56 LY# [003] 56 DP b# 56 intravenous acetaminophen 56 systemically administered 56 prospectively defined 56 INCB# [001] 56 renin inhibitors 56 epoetin alpha 56 ruboxistaurin 56 LHRH antagonists 56 phase IIa 56 sulodexide 56 ESBA# 56 TAXUS Liberte Stent 56 Bezielle 56 Phase Ib II 56 TriRima 56 eritoran 56 selective androgen receptor modulator 56 PET tracers 56 sipuleucel T 56 histone deacetylase HDAC inhibitor 56 OMS# 56 AVERROES 56 PROSTASCINT 56 dose proportionality 56 INCB# [002] 56 tesmilifene 56 selective modulator 56 CT perfusion 56 Aclidinium 56 CIMZIA TM 56 COR Analyzer 56 multimodality imaging 56 regorafenib 56 resynchronization therapy 56 tacrolimus ointment 56 eplerenone 56 tumor hypoxia 56 tolerability pharmacokinetics 56 Zyclara 56 Edwards SAPIEN valve 56 fibrinolytic 56 otelixizumab 56 PROMACTA 56 nonclinical studies 56 Eltrombopag 56 FDG PET scans 56 PDE4 inhibitor 56 ZACTIMA 56 ongoing Phase 1b 56 Tekamlo 56 Octreolin 56 intravenous cyclophosphamide 56 SYNTAX trial 56 Kynapid 56 OmniWave 56 ExTRACT TIMI 56 oral salmon calcitonin 56 Phase IIB 56 PHX# 56 latanoprost 56 MKC# MKC# PP 56 FDG-PET/CT 56 Linjeta 56 Intravail R 56 epinastine 56 prospective multicenter randomized 56 ELIQUIS 56 thetreatment 56 pharmacodynamic biomarkers 56 VIAject 56 plasma kallikrein 56 SRT# [003] 56 OncoVEX GM CSF 56 IMPACT DCM 56 pradefovir 56 SPIRIT FIRST 56 targeted radiotherapeutic 56 PXD# 56 pretargeting 56 Xanafide 56 BAY #-# 56 microdose 56 SinuNase 56 Cleviprex TM clevidipine 56 neuroprotectant 56 Nasulin 56 peptide BNP 56 photocoagulation 56 ixabepilone 56 midstage trials 56 Sym# 56 canakinumab 56 CardioPET 56 mGlu2 3 56 Vaxfectin TM 56 Ceflatonin 56 vascular disrupting agents 56 oral ridaforolimus 56 antitumor effect 56 Phase IIIb clinical 56 motesanib 56 PS# DARA 56 PICSO ® 56 Panzem R NCD 56 Pertuzumab 56 bi ventricular pacing 56 Removab 56 cardioprotective effects 56 ancrod 56 MERLIN TIMI 56 Archexin 56 Phase III ADT 56 pediatric malignancies 56 nitric oxide donating prostaglandin 56 atrasentan 56 bucindolol 56 aclidinium 56 JAK2 inhibitor 56 JAK2 inhibitors 56 ALTROPANE 56 ORMD 56 lesinurad 56 CoFactor 56 DU #b 56 Anavex #-# 56 mTOR inhibitors 56 Anturol TM 56 eTag assays 56 Phase #b/#a clinical 56 iroxanadine 56 secretin 56 PreCISe 56 renal artery stenting 56 resolvins 56 prospective randomized multicenter 56 Teriflunomide 56 thalidomide Thalomid 55 GLPG# 55 incyclinide 55 synthetic retinoid 55 levodopa induced dyskinesia 55 Vimpat R 55 HGS ETR1 55 optimal dosing regimens 55 Catena ® 55 induced macular edema 55 APOPTONE 55 PhG alpha 1 55 ONTARGET 55 Phase IIb clinical trials 55 decitabine 55 ZYBRESTAT TM 55 r hGH 55 olaparib 55 SUTENT ® 55 pharmacodynamic endpoints 55 Abbott bioabsorbable stent 55 depsipeptide 55 PEGylated interferon 55 ILLUMINATE 55 Non inferiority 55 stratifying patients 55 Ceplene/IL-2 55 Revascor TM 55 recombinant tissue plasminogen 55 Rigel R# 55 TM Drug Eluting 55 darapladib 55 NEVO TM 55 nalbuphine ER 55 anti androgens 55 Bicifadine 55 HSP# inhibitor 55 Urocortin 2 55 GRN# 55 Nesiritide 55 PROSTVAC TM 55 TLK# 55 radiotherapeutic 55 photodynamic therapy PDT 55 myeloperoxidase 55 Randomized clinical trials 55 KB# [002] 55 OncoVEX 55 AutoloGel tm 55 Seliciclib 55 gemcitabine Gemzar ® 55 nonrandomized 55 CRLX# 55 perfusion imaging 55 flecainide 55 myocardial revascularization 55 dexpramipexole 55 oral methylnaltrexone 55 vernakalant hydrochloride 55 CAPHOSOL 55 p# biomarker 55 radiation sensitizer 55 molecularly targeted 55 dose titration 55 HGS ETR2 55 Perceiva 55 Corlux 55 Angiocept 55 GnRH agonists 55 antiangiogenic agent 55 MEND CABG 55 aspirin clopidogrel 55 Xinlay 55 cardiac magnetic resonance 55 TWYNSTA 55 Sestamibi 55 INTERCEPT platelets 55 lipid lowering agents 55 biomarker 55 Alvesco R 55 reslizumab 55 nesiritide 55 iSONEP 55 optical coherence tomography OCT 55 metastatic malignant 55 APPRAISE 55 BEMA TM Fentanyl 55 pemetrexed Alimta 55 myoblast therapy 55 BLA filing 55 thymalfasin 55 malignant ascites 55 histone deacetylase inhibitor 55 cardiac perfusion 55 randomized blinded 55 Virulizin ® 55 AMN# [001] 55 GAP #B# 55 motesanib diphosphate 55 Photodynamic therapy PDT 55 vemurafenib 55 avosentan 55 cTnI 55 alefacept 55 Dapagliflozin 55 concurrent chemoradiation 55 Cinquil 55 trodusquemine 55 GALNS 55 cangrelor 55 Prostate AdenoCarcinoma Treatment 55 ablative therapy 55 direct thrombin inhibitors 55 efficacy endpoint 55 Tyrima 55 Ampakine 55 rtPA 55 Nanocort 55 NeutroSpec 55 biliary tract cancer 55 p# inhibitor 55 schizophrenia CIAS 55 aflibercept 55 torezolid phosphate 55 calcitonin 55 rhThrombin 55 Nanobody ® 55 desvenlafaxine 55 topical formulation 55 EGS# 55 LibiGel ® 55 Zolinza 55 EDEMA3 trial 55 OMP #M# 55 GED aPC 55 dose escalation phase 55 RE LY 55 sorafenib tablets 55 Arranon 55 Cardiolite 55 Symadex 55 AZILECT R 55 Vandetanib 55 Pyridorin 55 belinostat 55 anti CD3 antibody 55 Tasigna prolongs 55 VEGF inhibitor 55 Debio 55 Onrigin 55 pharmacodynamic parameters 55 CINQUIL 55 antiresorptive 55 pivotal bioequivalence 55 oxypurinol 55 triphendiol 55 cancer neuroendocrine tumor 55 intensive statin therapy 55 skin sterol 55 Phase 1a clinical 55 laropiprant 55 glycated hemoglobin levels 55 surrogate endpoint 55 drug eluting stent DES 55 Monitoring ABPM 55 subcutaneous ORENCIA 55 aleglitazar 55 insulin sensitizing 55 CLIRS trial 55 vinorelbine tartrate 55 Velcade bortezomib 55 prospective randomized controlled 55 Fingolimod 55 vascular disrupting agent 55 ACTOS ® 55 azilsartan medoxomil 55 axitinib 55 ASSERT trial 55 antiplatelet agent 55 Guanilib 55 arzoxifene 55 KRAS status 55 FDG PET 55 Phase III randomized controlled 55 Septin 9 55 Factor VIIa 54 Thrombolysis 54 Pharmacokinetic parameters 54 Paliperidone ER 54 PEARL SC 54 carotid artery stenting 54 SYMMETRY trial 54 edifoligide E2F Decoy 54 eltrombopag 54 Aptocine 54 Aquavan Injection 54 BRAF inhibitors 54 ximelagatran 54 custirsen 54 gepirone ER 54 miRview mets 54 CRx 54 Deforolimus 54 transdermal estradiol 54 Coronary CTA 54 GW# [003] 54 Bortezomib 54 XYOTAX TM 54 MGN# 54 carotid endarterectomy CEA 54 RH1 54 BioMAP 54 cardiac troponin 54 recurrent GBM 54 etanercept Enbrel 54 PMA submission 54 glycoprotein IIb IIIa inhibitor 54 FIRMAGON R 54 investigational therapies 54 HORIZONS AMI trial 54 CD# antibody [001] 54 Abiraterone acetate 54 Methylnaltrexone 54 AST ALT 54 Dabigatran etexilate 54 Genentech Roche 54 CTAP# Capsules 54 PROactive study 54 CytoFab ™ 54 DCCR 54 dual endothelin receptor antagonist 54 balsalazide tablet 54 Icatibant 54 hemostatic efficacy 54 wilate ® 54 masitinib 54 multicenter randomized placebo controlled 54 PI3K inhibitors 54 atherosclerosis regression 54 GVAX 54 bardoxolone 54 ADVEXIN therapy 54 CEQ# 54 dose escalation clinical 54 maximal dose 54 pharmacokinetic characteristics 54 dalbavancin 54 Xcellerated T Cells 54 oral FTY# 54 antiplatelet therapies 54 PLX cells 54 convenient dosing regimens 54 sorafenib Nexavar 54 ZFP TF 54 bioequivalency 54 OMP #R# 54 VEGF receptor 54 Erbitux cetuximab 54 adecatumumab 54 CellSearch System 54 Kahalalide F 54 DXL# 54 LDL lowering 54 HuCAL antibodies 54 IL 1ß 54 ospemifene 54 K ras mutations 54 glufosfamide 54 Phase #b/#a trial 54 Telatinib 54 postmarketing surveillance 54 rt PA 54 morphometric vertebral fractures 54 Onconase 54 neuroregenerative 54 unblind 54 ISIS # 54 LEVADEX ™ 54 elacytarabine 54 vismodegib 54 EndoTAG TM -1 54 XL# SAR# 54 Pazopanib 54 GRAVITAS trial 54 AOD# [002] 54 BFPET 54 endothelin antagonists 54 trabectedin 54 Zemplar Capsules 54 CINTREDEKIN BESUDOTOX 54 dexanabinol 54 EndoTAGTM 1 54 PFO migraine 54 rBChE 54 fluvastatin 54 Vectibix panitumumab 54 Urocidin 54 BARI 2D 54 PEG PAL 54 somatostatin analogues 54 Fx #A 54 Tarceva TM 54 mGluR2 NAM 54 immunohistochemical 54 Clinicaltrials.gov 54 ABSORB trial 54 Onalta 54 AP# [003] 54 Zemiva imaging 54 TNF inhibitor 54 RIGScan CR 54 APPROVe 54 fidaxomicin Phase 3 54 Bucindolol 54 Neuradiab 54 biodistribution 54 UPLYSO 54 Posiphen 54 ThermoDox R 54 Liprostin 54 ACRIN 54 unoprostone isopropyl 54 LMWH 54 PD2i ® 54 Zometa zoledronic acid 54 PEG IFN 54 pharmacodynamic properties 54 DNA methylation markers 54 Exforge HCT 54 ischemic cardiomyopathy 54 EECP ® therapy 54 symptomatic paroxysmal AF 54 multidose 54 confirmatory clinical 54 Amgen denosumab 54 Carotid 54 Ostarine 54 Subgroup analysis 54 ARRY 54 pitavastatin 54 BRIM3 54 cystoscopic 54 proton MR spectroscopy 54 interventional therapies 54 Saforis 54 Randomized Phase 54 ACUITY trial 54 angiography CCTA 54 NanoCrystal Technology 54 squalamine 54 VEGF Trap 54 lapatinib Tykerb 54 Xcytrin R 54 ivabradine 54 Desmoteplase 54 Embolic Protection Device 54 novel oral anticoagulant 54 urocortin 2 54 Temsirolimus 54 trastuzumab DM1 T DM1 54 IV Busulfex 54 Cloretazine 54 PCWP 54 anidulafungin 54 fulvestrant 54 ALTTO 54 Squalamine 54 randomized Phase IIb 54 novel VDA molecule 54 CDK inhibitor 54 Crizotinib 54 solanezumab 54 biochemical markers 54 photoprotective drug 54 Plicera 54 Bevacizumab 54 OvaRex R 54 Carvedilol 54 Tezampanel 54 anticancer therapy 54 Aggressive Drug Evaluation 54 Lp PLA2 54 computed tomographic 54 aerosolized KL4 surfactant 54 Flow cytometry 54 multicenter randomized controlled 54 Evoltra 54 GORE VIABAHN Endoprosthesis 54 chemoradiation therapy 54 omega interferon 54 Phase IIa trials 54 D dimer 54 subcutaneous PRO 54 RE LY trial 54 angiogenesis inhibitor 54 IMA# 54 postmenopausal osteoporotic women 54 IMC A# 54 mg/m2 cohort 54 maximally tolerated dose 54 Viprinex TM 54 optimal dosing 54 Asentar 53 Cypher Stent 53 TLR antagonists 53 retaspimycin 53 myelofibrosis polycythemia vera 53 Cand5 53 multicenter trials 53 PREDICTIVE 53 inhibit metastasis 53 CIMZIA TM certolizumab pegol 53 OMS#HP 53 antisense oligonucleotide 53 AIM HIGH 53 #F FDG PET 53 rALLy trial 53 aplindore 53 CardioFit 53 TRV# [001] 53 Rivaroxaban 53 blinatumomab 53 pharmacokinetic equivalence 53 guanfacine extended release 53 molecular imaging radiopharmaceutical 53 Danazol 53 Hsp# inhibition 53 chemosensitivity 53 florbetapir F 53 Liposomal 53 bazedoxifene 53 anti CD# antibodies 53 Perforomist ™ Inhalation Solution 53 zileuton CR 53 PREOS R 53 HDL Selective Delipidation 53 rhIGF-I/rhIGFBP-3 53 natriuretic peptide 53 AQ4N 53 antiplatelet drugs 53 AGGRASTAT ® 53 HDL Mimetic Peptide 53 procalcitonin 53 topical formulations 53 Vasogen Celacade 53 efalizumab 53 Alair System 53 flavopiridol 53 delafloxacin 53 AGGRASTAT R 53 AEG# 53 BrachySil ™ 53 preoperative MRI 53 Achieves Primary Endpoint 53 Combidex 53 antithrombotic 53 NEXTERONE 53 proteasome inhibitor 53 idraparinux 53 NMIBC 53 DaTSCAN 53 FOLOTYN ® 53 novel peptide 53 HQK 53 DVT prophylaxis 53 TASKi3 53 SAR# [004] 53 receptor tyrosine kinase inhibitor 53 phase Ib 53 teriparatide 53 chemopreventive agent 53 tubulin inhibitor 53 ADCIRCA 53 TLR antagonist 53 initiate Phase 1b 53 VerifyNow P#Y# Test 53 Neurodex 53 Rasagiline 53 GSK# [002] 53 acute coronary syndromes ACS 53 midstage clinical trials 53 CD# monoclonal antibody 53 intravitreal triamcinolone 53 MIST II 53 radiotracer 53 figitumumab 53 LUMINATE 53 assessing T DM1 53 fenretinide 53 recurrent glioblastoma multiforme 53 intravitreal bevacizumab 53 alemtuzumab MS 53 dimeglumine 53 noninvasive diagnostic 53 clinically meaningful 53 antidepressant efficacy 53 Vitaxin 53 subanalysis 53 Amplimexon 53 OXi# 53 PREVU x LT 53 dose cohort 53 ReoPro 53 PDE# inhibitors 53 Huntexil 53 Inhaled nitric oxide 53 antithrombotic therapy 53 NEBIDO 53 tolevamer 53 bevacizumab Avastin ® 53 MVax 53 briakinumab 53 indacaterol 53 Clolar ® 53 TAXUS VI 53 macrolide antibiotic 53 metabolite concentrations 53 molecular determinants 53 telaprevir VX 53 solithromycin 53 TRA 2P 53 intensive lipid lowering 53 microbubble 53 bendamustine 53 Acute Decompensated Heart Failure 53 KRAS mutation status 53 ZoMaxx 53 secretory phospholipase A2 sPLA2 53 VANOS TM 53 aldosterone antagonist 53 HoFH 53 PARTNER Trial 53 transesophageal 53 vascular ultrasound 53 KRAS mutation 53 NAVISTAR R 53 Hedgehog inhibitor 53 trastuzumab DM1 53 factor Xa 53 DPX Survivac 53 Cystatin C 53 anti arrhythmic drug 53 phase IIb 53 CATIE AD 53 angiotensin receptor blockers ARBs 53 RIGScan 53 retinal vein occlusion induced 53 Ixempra 53 percutaneous interventions 53 IMP# 53 PITX2 methylation 53 murine model 53 Elesclomol 53 hyperacute 53 Noxafil 53 intravenous tPA 53 MEK inhibitor RDEA# 53 nucleotide analog 53 anti amnesic 53 MACUGEN 53 Zilver PTX stent 53 A3 adenosine receptor 53 BACcel 53 Hedgehog antagonist 53 multicentre randomized 53 neostigmine 53 generation purine nucleoside